Amunix, Inc. Announces Extension Of Evaluation Agreement With Roche (RHHBY)
Amunix Establishes GMP Manufacturing of XTEN™ at UN-L BPDF
Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Growth-Hormone-XTEN (VRS-317, Somavaratan) in Children.
XTEN is a proprietary recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins